What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Consumer Goods

PUBLISHER: 360iResearch | PRODUCT CODE: 2085415

PUBLISHER: 360iResearch | PRODUCT CODE: 2085415

Cryogenic Vials Market by Thread Type, Material, Volume, Sterility, Closure, Automation Compatibility, Application, End User - Global Forecast 2026-2032

PUBLISHED: July 10, 2026

PAGES: 182 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Cryogenic Vials Market is projected to grow by USD 892.98 million at a CAGR of 6.28% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 582.67 million
Estimated Year [2026]	USD 618.15 million
Forecast Year [2032]	USD 892.98 million
CAGR (%)	6.28%

The cryogenic vials market is being shaped by the rapid expansion of biobanking, precision medicine, vaccine development, reproductive medicine, and cell and gene therapy manufacturing. Cryogenic vials, also known as cryovials or cryogenic storage tubes, are essential consumables for preserving biological samples at ultra-low temperatures, including vapor-phase liquid nitrogen and mechanical freezer conditions.

Demand is closely linked to the growth of clinical research and long-term biospecimen storage. Verified industry drivers include the global rise in chronic disease research, broader use of genomic and proteomic workflows, and stricter requirements for sample traceability under frameworks such as ISO 20387 for biobanking, ISO 13485 for medical device quality management, and 21 CFR Part 11 for electronic records in regulated environments.

Transformative Shifts in the Cryogenic Storage Landscape

The competitive landscape is moving from basic storage tubes toward engineered cryogenic vial systems that improve sample integrity, automation compatibility, and contamination control. Laboratories increasingly prefer sterile, DNase/RNase-free, non-pyrogenic polypropylene cryovials with secure closures, barcoding options, and formats compatible with automated storage and retrieval systems.

A major shift is the move toward closed, traceable, and validated cold-chain workflows. Biobanks, pharmaceutical manufacturers, fertility clinics, and academic research centers are prioritizing external-thread and internally sealed vial designs, 2D-coded tubes, tamper-evident packaging, and validated sterilization methods aligned with ISO 11137 or ISO 11135, depending on product design and sterilization modality.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasing the strategic value of cryogenic vials by improving sample inventory management, predictive maintenance, and cold-chain quality assurance. AI-enabled laboratory information management systems can connect cryovial identifiers, freezer locations, freeze-thaw history, chain-of-custody records, and assay outcomes to reduce sample loss and improve reproducibility.

The cumulative impact is strongest where cryogenic storage supports high-value samples such as cell therapy starting materials, tumor specimens, stem cells, and longitudinal cohort samples. AI-driven demand planning also helps align production of sterile cryogenic vials, caps, racks, and compatible storage systems with research cycles, clinical trial enrollment, and biomanufacturing capacity planning.

Key Regional Insights

Asia-Pacific is gaining momentum as China, India, Japan, South Korea, and Australia expand biomedical research, clinical trial infrastructure, and biomanufacturing capacity. The region benefits from rising public and private investment in genomics, oncology, vaccine research, and regenerative medicine, increasing demand for sterile cryogenic vials and automated sample storage formats.

North America remains a leading region due to advanced biobanking networks, strong pharmaceutical and biotechnology activity, established clinical trial operations, and regulatory expectations for validated sample handling. Europe is defined by mature research institutions, GDPR-driven data governance, biobank quality programs, and the transition to IVDR compliance for in vitro diagnostic workflows. Latin America, led by Brazil and Mexico, is growing through infectious disease surveillance, cancer research, vaccine programs, and clinical laboratory modernization. The Middle East is investing in precision medicine, fertility services, and hospital research infrastructure, while Africa's growth is tied to public health surveillance, pathogen repositories, genomic epidemiology, and international research collaborations.

Key Group Insights

ASEAN demand is supported by expanding hospital networks, infectious disease research, and biopharma investment in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. GCC countries are advancing precision medicine, fertility care, population health initiatives, and national health transformation programs, creating opportunities for high-quality cryogenic sample storage consumables.

The European Union emphasizes regulatory compliance, sustainability, data protection, and harmonized quality systems, making certified sterile cryovials and traceable storage solutions especially important. BRICS countries are significant because they combine large patient populations with expanding clinical research ecosystems, vaccine capabilities, and biomanufacturing infrastructure. G7 markets represent high-value demand for advanced cryogenic vial formats used in biopharmaceutical R&D, cell therapy, clinical biobanking, and academic medicine, while NATO-aligned procurement environments often prioritize supply resilience, standardization, and validated cold-chain logistics for biomedical readiness.

Key Country Insights

The United States leads through strong publicly funded biomedical research, FDA-regulated biopharmaceutical development, and extensive biobank and clinical trial networks, while Canada benefits from academic medical centers, population health research, and regenerative medicine programs. Mexico and Brazil are important Latin American growth markets supported by laboratory modernization, population-scale health research, vaccine activity, and infectious disease programs.

In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on advanced biomedical research, hospital biobanking, and pharmaceutical manufacturing, while Russia maintains demand through domestic research and clinical laboratory infrastructure. China and India are expanding rapidly due to genomics, vaccine production, clinical trials, and biomanufacturing scale. Japan, South Korea, and Australia contribute high-value demand through precision medicine, oncology research, stem cell science, quality-driven laboratory procurement, and automated sample storage adoption.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated cryogenic vial portfolios that address contamination prevention, traceability, automation compatibility, and regulatory documentation. Product strategies should include sterile and non-sterile options, external-thread and internal-thread formats, 2D-coded cryovials, validated packaging, and compatibility with liquid nitrogen vapor storage and ultra-low-temperature freezers.

Manufacturers should strengthen quality evidence, including extractables and leachables data, sterilization validation, lot traceability, and freezer compatibility testing. Commercial teams should focus on biobanks, cell and gene therapy manufacturers, fertility clinics, contract research organizations, and academic research centers, while supply chain teams should improve regional inventory planning to mitigate disruptions in polypropylene resin, caps, inserts, labels, and packaging materials.

Research Methodology

This executive summary is developed using a structured secondary research approach that synthesizes verified public-domain and standards-based evidence. Sources considered include regulatory frameworks, international standards, public health agencies, clinical research infrastructure indicators, and established industry practices for cryogenic sample storage and biobanking.

The methodology emphasizes triangulation across demand drivers, end-user adoption patterns, regional research infrastructure, and compliance requirements. Market interpretation is grounded in observable factors such as biopharmaceutical R&D activity, clinical trials, biobank accreditation, cell therapy development, laboratory automation, and cold-chain quality management rather than unsupported assumptions.

Conclusion

Cryogenic vials are becoming strategic enablers of modern life science research, diagnostics, and biomanufacturing. As biological samples become more valuable and data-linked, buyers are prioritizing cryovials that protect sample integrity, support traceability, and integrate with automated cold-storage ecosystems.

The strongest opportunities will favor suppliers that combine material quality, validated sterility, regulatory documentation, automation-ready design, and dependable global availability. Organizations that align cryogenic vial innovation with biobanking, precision medicine, and cell and gene therapy workflows are positioned to address durable demand across developed and emerging regions.

Product Code: MRR-4311CE1A33F4

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cryogenic Vials Market, by Thread Type

7.1. Internal Thread Cryogenic Vials
7.2. External Thread Cryogenic Vials

8. Cryogenic Vials Market, by Material

8.1. Glass
- 8.1.1. Borosilicate
- 8.1.2. Soda Lime
8.2. Plastic
- 8.2.1. Polyethylene
- 8.2.2. Polypropylene

9. Cryogenic Vials Market, by Volume

9.1. 1.5ml
9.2. 10ml
9.3. 2ml
9.4. 5ml

10. Cryogenic Vials Market, by Sterility

10.1. Non Sterile
10.2. Sterile

11. Cryogenic Vials Market, by Closure

11.1. Magnetic Closure
11.2. O Ring
11.3. Screw Cap
11.4. Snap Cap

12. Cryogenic Vials Market, by Automation Compatibility

12.1. Fully Automated
12.2. Manual
12.3. Semi Automated

13. Cryogenic Vials Market, by Application

13.1. Cryopreservation
13.2. Sample Storage
13.3. Transport

14. Cryogenic Vials Market, by End User

14.1. Academic & Research Institutes
14.2. Biobanks
14.3. Diagnostic Laboratories
14.4. Hospitals & Clinics
14.5. Pharmaceutical & Biotechnology Companies

15. Cryogenic Vials Market, by Region

15.1. Asia-Pacific
15.2. North America
15.3. Latin America
15.4. Europe
15.5. Middle East
15.6. Africa

16. Cryogenic Vials Market, by Group

16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO

17. Cryogenic Vials Market, by Country

17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
- 18.1.1. Concentration Ratio (CR)
- 18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025

19. Company Profiles

19.1. Abdos Labtech Private Limited
19.2. Argos Technologies, Inc.
19.3. Azenta Life Sciences, Inc.
19.4. Bio Plas, Inc.
19.5. BioCision, LLC
19.6. Capp ApS
19.7. CELLTREAT Scientific Products
19.8. Corning Incorporated
19.9. DWK Life Sciences GmbH
19.10. Electron Microscopy Sciences, LLC
19.11. Eppendorf AG
19.12. EZ BioResearch LLC
19.13. Globe Scientific Inc.
19.14. Greiner Bio-One International GmbH
19.15. Hamilton Company
19.16. Heathrow Scientific LLC
19.17. IMV Technologies Group
19.18. Labcon North America, Inc.
19.19. LVL Technologies GmbH & Co. KG
19.20. Micronic Holding B.V.
19.21. NEST Scientific USA, Inc.
19.22. Sigma-Aldrich Corporation
19.23. Simport Scientific, Inc.
19.24. Starlab International GmbH
19.25. Sumitomo Bakelite Co., Ltd.
19.26. Thermo Fisher Scientific, Inc.
19.27. USA Scientific, Inc.
19.28. VWR International, LLC